AstraZeneca Shares Plunge 7.4% After Heart Drug Trial Fails—July 10

AstraZeneca shares tumbled 7.4% on July 9 after the company announced its heart disease drug Wainua failed to reduce cardiovascular deaths in a late-stage trial. The setback wiped £14 billion from market value and raised questions about management credibility, despite the company’s strong track record in oncology. Jefferies analysts estimate the miss could cost the company $2.5 billion in risk-adjusted sales.

What went wrong with Wainua

Wainua, co-developed with Ionis Pharmaceuticals, failed to meet its primary endpoint in the CARDIO-TTRansform trial. The drug did not reduce cardiovascular deaths and recurrent heart events over 140 weeks in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) when added to standard care. The trial enrolled nearly 1,500 patients randomized to receive eplontersen or placebo every four weeks.

Why credibility matters more than lost sales

Jefferies analysts noted the bigger issue is probably a degree of credibility loss, since AstraZeneca had been very confident in the trial’s ability to hit the primary endpoint. Under CEO Pascal Soriot’s 14-year leadership, the company rarely posts negative trial results. This surprise disappointment may have ripple effects beyond Wainua itself, shaking investor trust in management’s confidence calls.

Meyka data shows limited downside from here

Meyka grades AstraZeneca B+ with a neutral recommendation, forecasting the stock at $131.71 by year-end. The RSI sits at 43.86, indicating neither overbought nor oversold conditions. At a 26.7 trailing P/E ratio, the stock trades above its 50-day average of £184.11 but well below the 52-week high of £212.71, suggesting room for recovery once trial uncertainty clears.

Rival drug makers gain competitive edge

BridgeBio surged 16% on the news as competitors benefit from the failed trial. Alnylam’s ATTR silencer franchise strengthens its competitive position, with Raymond James raising its price target to $468 from $420. The ATTR-CM market was valued at $15 billion-plus, and Wainua’s failure reshapes the competitive landscape for rival treatments.

Final Thoughts

AstraZeneca’s trial failure is a credibility hit rather than a revenue killer, with Jefferies modeling only $2.5 billion in lost sales against an $80 billion 2030 target. Meyka’s B+ grade and $131.71 year-end forecast suggest the stock has room to recover once sentiment stabilizes.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.